Evaluation of a 64Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model

  • Authors:
    • Min Hwan Kim
    • Ji Ae Park
    • Sang‑Keun Woo
    • Kyo Chul Lee
    • Gwang Il An
    • Byoung Soo Kim
    • Kwang Il Kim
    • Tae Sup Lee
    • Chan Wha Kim
    • Kyeong Min Kim
    • Joo Hyun Kang
    • Yong Jin Lee
  • View Affiliations

  • Published online on: January 9, 2015     https://doi.org/10.3892/ijo.2015.2832
  • Pages: 1159-1168
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastrin‑releasing peptide receptor (GRPR) is overexpressed by a variety of human tumors and in particular, identified to be upregulated in prostate cancers. The current study aimed to develop clinically translatable BBN analogue‑based radioligands for positron emission tomography (PET) of GRPR‑positive tumors. We developed radiolabeled BBN analogues and modified radiolabeled galacto‑BBN analogues and then investigated their tumor‑targeting efficacy in vivo. The chelator 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA) was used to radiolabel the peptides with 64Cu. The peptides were evaluated by measuring cell‑based receptor‑binding affinities. Biodistribution experiments and small animal imaging using PET were performed in nude mice bearing subcutaneous PC3 human prostate cancer xenografts. The conjugates were radiolabeled with yields >99%. The stability assay showed that [64Cu]NODAGA‑BBN and [64Cu]NODAGA‑galacto‑BBN remained stable in both human and mouse serum for 1 h at 37˚C. PET images of PC3 tumor‑bearing nude mice were acquired at 1, 3, 24, 48 and 72 h after injection. [64Cu]NODAGA‑galacto‑BBN showed retention in tumors for 72 h, low liver uptake, and rapid renal clearance. PET imaging results were also confirmed by biodistrubution 1 and 3 h after injection. [64Cu]NODAGA‑BBN and [64Cu]NODAGA‑galacto‑BBN are promising new PET probes for GRPR‑positive prostate cancer.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 46 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kim MH, Park JA, Woo SK, Lee KC, An GI, Kim BS, Kim KI, Lee TS, Kim CW, Kim KM, Kim KM, et al: Evaluation of a 64Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model. Int J Oncol 46: 1159-1168, 2015.
APA
Kim, M.H., Park, J.A., Woo, S., Lee, K.C., An, G.I., Kim, B.S. ... Lee, Y.J. (2015). Evaluation of a 64Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model. International Journal of Oncology, 46, 1159-1168. https://doi.org/10.3892/ijo.2015.2832
MLA
Kim, M. H., Park, J. A., Woo, S., Lee, K. C., An, G. I., Kim, B. S., Kim, K. I., Lee, T. S., Kim, C. W., Kim, K. M., Kang, J. H., Lee, Y. J."Evaluation of a 64Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model". International Journal of Oncology 46.3 (2015): 1159-1168.
Chicago
Kim, M. H., Park, J. A., Woo, S., Lee, K. C., An, G. I., Kim, B. S., Kim, K. I., Lee, T. S., Kim, C. W., Kim, K. M., Kang, J. H., Lee, Y. J."Evaluation of a 64Cu‑labeled 1,4,7‑triazacyclononane, 1‑glutaric acid‑4,7 acetic acid (NODAGA)‑galactose‑bombesin analogue as a PET imaging probe in a gastrin‑releasing peptide receptor‑expressing prostate cancer xenograft model". International Journal of Oncology 46, no. 3 (2015): 1159-1168. https://doi.org/10.3892/ijo.2015.2832